Dashyant Dhanak, who has served as Incyte’s chief scientific officer since 2018, will be leaving the organization effective August 2 in order to pursue other interests. Under his leadership, Incyte has filed more than fifteen Investigational new drug applications, and has made advancements in the biotherapeutics and small molecule pipeline.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on INCY:
- Notable companies reporting before tomorrow’s open
- Incyte, Replimune enter clinical collaboration for RP1 and INCB99280 in CSCC
- INCY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Disney downgraded, Meta Platforms upgraded: Wall Street’s top analyst calls
- Incyte initiated with a Buy at Citi